Companies

SAB Biotherapeutics, Inc.

SABS, SABSW · CIK 0001833214 · operating

$4.07-0.73%Last updated Mar 2, 8:48 PM

Key Statistics

Valuation

Market Cap$193.76M
P/E
Fwd P/E-13.57
PEG
P/S1689.30
P/B1.17
EV/EBITDA-2.22
EV/Rev776.53

Profitability

Gross Margin
Op. Margin-3244.87%
Net Margin-2579.03%
ROE-131.33%
ROA-77.17%
FCF Margin-2618.65%

Financial Health

Current Ratio2.98
Debt/Equity0.70
Free Cash Flow-$34.63M
Div. Yield

Growth & Other

Revenue Growth-40.94%
EPS Growth51.83%
Beta0.61
52W High$6.6
52W Low$1

About SAB Biotherapeutics, Inc.

SAB Biotherapeutics, Inc. (SABS) is a biological products, (no diagnostic substances) company incorporated in DE, listed on the Nasdaq. With a market capitalization of $187 million, SAB Biotherapeutics, Inc. is a micro-cap company. The stock currently trades at $4.07, down 0.73% today, with a 52-week range of $1.00–$6.60.

Earnings Per Share (Annual · SEC XBRL)

Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.

Fiscal YearEPS DilutedEPS BasicYoY
2024$-3.68$-3.68+51.8%
2023$-7.64$-7.64-1676.7%
2022$-0.43+31.7%
2021$-0.63$-0.63
2020

Annual Reports (10-K) · 5 filings

Report DateFiledAccession Number
2024-12-312025-03-310000950170-25-046994SEC ↗
2023-12-312024-03-290000950170-24-038219SEC ↗
2022-12-312023-04-140001437749-23-010343SEC ↗
2021-12-312022-03-290000950170-22-004935SEC ↗
2020-12-312021-04-020001493152-21-007884SEC ↗